A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

Trial Profile

A Phase 2 Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (ALCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Anaplastic large cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 06 Dec 2016 End of study results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Dec 2016 According to a Seattle Genetics media release, five-year overall survival data from this trial were presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition
    • 05 Dec 2016 Results published in the Seattle Genetics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top